Novel Analogues of the Asthma Drug Fenoterol as Liver and Brain Cancer Therapeutic Agents


Available for licensing are specific fenoterol analogues, such as MNF, that inhibit the growth of various types of cancers, including brain, liver, colon, and lung tumors. MNF acts as an agonist of the GPRSS cannabinoid (CB) receptor and, as such, represents one of the first potential drugs directed at this target. MNF crosses the blood brain barrier and initial toxicity studies indicate that it has few off-target effects. These new analogues can be used to treat CB receptor related disorders and diseases, and in particular GRPSS-related disorders and diseases, including brain and liver cancers for which there are no current effective treatments.

Potential Commercial Applications: Competitive Advantages:
  • A new class of compounds that can be used to treat cannabinoid receptor related disorders and diseases.
  • Treatments for liver, brain, colon, and lung cancers.
 
  • Able to cross the blood:brain barrier.
  • Few side-effects.
  • Broad range of therapeutic activity.
  • Can be formulated for oral administration.


Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Irving Wainer (NIA)  ➽ more inventions...

Michel Bernier (NIA)  ➽ more inventions...

Rajib Paul (NIA)  ➽ more inventions...


Intellectual Property:
US Application No. 61/651,961

Publications:
Paul RK, et al. Cannabinoid receptor activation correlates with the pro-apoptotic action of the beta2-adrenergic agonist (R,R')-4'-methoxy-1-naphthylfenoterol. J Pharmacol Exp Ther., in press.
Paul RK, et al. Negative regulation of GPR-55-mediated ligand uptake and cellular motility by (R,R')-4'-methoxy-1-napthylfenoterol. Br J Pharmacol., in preparation.
Paul RK, et al. The role of GPR55 and apoptotic signalling pathways in (R,R')-4'-methoxy-1-naphthyfenoterol. Cancer Res., in preparation.

Collaboration Opportunity:

The IRP/NIA/LCI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize (R,R')-4'-methoxy-1-naphthylfenoterol for the treatment of brain, liver and colon carcinomas. For collaboration opportunities, please contact Nicole Guyton, Ph.D. at darackn@mail.nih.gov. Click here to view the NIA collaborative opportunity announcement.


Licensing Contact:
Charlotte McGuinness, Ph.D., J.D.
Email: cm432k@nih.gov
Phone: 240-276-5530

OTT Reference No: E-139-2012/0
Updated: Aug 1, 2012